A trusted resource for modern practices

← Aesthetic InjectablesObagi Medical

Hyaluronic acid dermal fillers

European heritage.
Purpose-built
facial precision.

MagIQ™ and ChIQ™ bring Austrian-developed HA technology to the U.S. through a focused two-product portfolio for lower-face correction and midface structure.

Request Obagi filler informationOfficial Obagi information ↗
Obagi MagIQ and ChIQ dermal filler syringes

Limited-time launch promotion

Obagi filler special

Extended through October 31, 2026

MagIQ™ + ChIQ™$180

per syringe

Combine launch pricing with complimentary filler samples.

MagIQ and ChIQ purchases may be mixed and matched to qualify.

Tier 1Buy 20

Receive 4 ChIQ samples

Tier 2Buy 30

Receive 6 ChIQ samples

Tier 3Buy 40

Receive 15 MagIQ or ChIQ samplesMix and match

Tier 4Buy 60

Receive 25 MagIQ or ChIQ samplesMix and match

Offer valid through October 31, 2026, or while supplies last. Available to qualified U.S. and Puerto Rico accounts; void where prohibited, taxed or restricted. Obagi may amend or end the offer at any time.

Contact ElleVie about this special

A global HA story

Established abroad.
New opportunity at home.

Known internationally as saypha®, the portfolio is developed by Croma-Pharma in Austria and introduced in the U.S. through Obagi Medical.

The line pairs European manufacturing heritage with a focused product strategy. For practices, that means two clearly differentiated gels, a familiar HA category and a compelling opportunity to deliver results while protecting treatment value.

Lower face · Wrinkles + folds

MagIQ™

Smooth, correct and refine.

Obagi® saypha® MagIQ™ is injected into the mid-to-deep dermis for correction of moderate-to-severe facial wrinkles and folds in adults over 21.

  • Nasolabial folds
  • Oral commissures and marionette lines
  • Mental crease and pre-jowl sulcus
  • Effectiveness demonstrated for up to 12 months in clinical trials
Obagi MagIQ packaging and syringe
Illustration showing Obagi MagIQ lower-face and ChIQ cheek treatment areas

Midface · Cheek augmentation

ChIQ™

Support, contour and restore.

Obagi® saypha® ChIQ™ is indicated for cheek augmentation and correction of midface contour deficiencies in adults over 21.

  • Antero-medial cheek
  • Zygomatico-malar region
  • Submalar region
  • Results lasted up to 48 weeks in most clinical-study subjects

The HA technology

Consistency designed into the gel.

Obagi describes its dermal fillers as a homogeneous HA portfolio with consistent particle sizing and a narrow particle-size distribution—qualities intended to support predictable handling and outcomes.

01

Homogeneous formulation

A smooth, uniform gel developed for consistent delivery.

02

Focused rheology

Two products selected for different structural needs and facial zones.

03

Lidocaine included

Each colorless HA gel contains a small amount of lidocaine to help reduce discomfort during treatment.

Obagi dermal filler syringes in blue and red

One focused filler portfolio

Two gels.
Distinct roles.

Rather than building a crowded shelf, MagIQ and ChIQ give practices a concise starting portfolio spanning foundational lower-face correction and midface volume.

MagIQ™Mid-to-deep dermisWrinkles + folds

ChIQ™Subcutaneous and/or supraperiostealCheek + midface

The ElleVie advantage

Introduce a new filler line with intention.

ElleVie helps practices evaluate portfolio fit, understand product differentiation and prepare injectors and staff for a confident launch.

01Portfolio planningIdentify where MagIQ and ChIQ complement your current HA mix.
02Product educationApproved uses, handling, treatment areas and clinical resources.
03Team positioningTranslate global heritage into a clear patient conversation.
04Practice economicsBuild pricing and treatment strategy around sustainable margins.

Important safety information

For licensed healthcare professionals.

APPROVED USES. MagIQ™ is a prescription injection into the mid-to-deep dermis for correction of moderate-to-severe facial wrinkles and folds, such as nasolabial folds, in adults over 21. ChIQ™ is a prescription injectable dermal filler for cheek augmentation and correction of midface contour deficiencies in adults over 21.

Do not use in patients with previous allergic reactions to HA fillers, severe allergies or anaphylaxis, allergy to lidocaine or gram-positive bacterial proteins, or bleeding disorders. Safety during pregnancy or breastfeeding has not been studied.

Common side effects include swelling, redness, pain, bruising, tenderness, firmness, lumps or bumps, discoloration and itching. Unintentional injection into a blood vessel is rare but can cause serious and potentially permanent complications, including vision abnormalities, blindness, stroke, scarring or skin necrosis.

Review complete Directions for Use and patient information ↗

Explore whether Obagi fillers are right for your practice.

Talk with ElleVie